ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Prostate Cancer

Biomarker Combo Could Predict Prostate Cancer Survival

A combination of biomarkers has shown promise as a surrogate for survival in clinical trials of metastatic castration-resistant prostate cancer. Image © Eugene Sim / Shutterstock.com.

Prostate Cancer

PSA-based screening for prostate cancer among men older than 50 has decreased since the 2012 USPSTF recommendations.

Enhanced control of osseous metastases with both systemic life-extending therapies and bone-support medications has meaningful clinical impact for prostate cancer patients.

Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223 and review the available data regarding the cost of denosumab compared with that of zoledronic acid.

Thanks to the efforts of the Prostate Cancer Foundation and Movember, men of good will (especially those inclined to grow mustaches and raise awareness and funds each year) and their physicians are newly energized to make progress.

A study showed that prostate cancer patients with bone metastases could have a long-term response to ADT and an acceptable quality of life for 10 or more years.

A small study found that the detection of AR-V7 in advanced prostate cancer patients is not associated with resistance to initial chemotherapy.

Men with prostate cancer assigned to intermittent ADT experienced more ischemic and thrombotic events than did men assigned to continuous ADT.

Pages

Subscribe to Prostate Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.